¹Department of Pharmaceutics, Krupanidhi College of Pharmacy, Rajiv Gandhi University of Health Sciences, Bengaluru 560035, India DOI : 10.29228/jrp.362 The major problems associated with the oral route of administration are low solubility, low permeability, and hepatic degradation of drugs, leading to low bioavailability issues. Therefore, in this study, a biopharmaceutics classification systems (BCS) class II drug aripiprazole was chosen to develop an oral disintegrating tablet using liquisolid technology to enhance the solubility and dissolution rate of the drug. Liquisolid compact of aripiprazole was prepared using polyethylene glycol (PEG 400) as a nonvolatile solvent, microcrystalline cellulose (MCC) as a carrier, and Aerosil 200 as a coating material. The formulations were optimized via the 23-factorial design. The optimum formulation was further converted to oral disintegrating tablets with the help of the super disintegrant, cross povidone, and the produced tablets were evaluated. The water solubility of aripiprazole was observed to have increased from 4.5μg/ml to 0.13mg/ml in the liquisolid form and angle of repose was found to be reasonably passable. As was observed from the experimental design, the solvent, solvent: carrier, and carrier were seen to have a significant influence on the selected responses. The X-ray diffraction pattern of the optimized formula indicated a reduction in the peak number and the peak intensities compared to the pure drug. The tablets prepared of liquisolid compacts displayed good tableting properties. The disintegration time was found to be 40 seconds. The stability studies indicated no apparent changes in the properties after a storage period of 3 months. The liquisolid compacts are an inexpensive method of preparing oral disintegrating tablets of Aripiprazole with an assurance of suitable dissolution property of the drug. Keywords : Aripiprazole; liquisolid compacts; oral disintegrating tablets; solubility; bioavailability